Proprietary drug candidates for cochlear synaptopathy

About CILcare

CILcare is a unique, dual-focus biotech company at the intersection of neuroscience and otology. It leverages deep expertise in auditory science to provide specialized preclinical CRO services to pharmaceutical partners while simultaneously developing its own proprietary drug candidates targeting cochlear synaptopathy and other hearing losses. The company is also pioneering a digital health initiative, Cilcare Auditory Analytics, aiming to create digital auditory signatures for precision diagnostics. Its validated models and collaborative approach have attracted partnerships with top-tier pharma and biotech companies.

Therapeutic Areas